Repligen Company Profile (NASDAQ:RGEN)

About Repligen (NASDAQ:RGEN)

Repligen logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RGEN
  • CUSIP: 75991610
  • Web:
  • Market Cap: $1.32 billion
  • Outstanding Shares: 34,080,000
Average Prices:
  • 50 Day Moving Avg: $36.76
  • 200 Day Moving Avg: $33.10
  • 52 Week Range: $21.11 - $39.96
  • Trailing P/E Ratio: 102.64
  • Foreward P/E Ratio: 53.97
  • P/E Growth: 2.74
Sales & Book Value:
  • Annual Revenue: $110.04 million
  • Price / Sales: 12.04
  • Book Value: $5.19 per share
  • Price / Book: 7.49
  • EBIDTA: $27.41 million
  • Net Margins: 6.89%
  • Return on Equity: 10.16%
  • Return on Assets: 6.87%
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 10.89%
  • Quick Ratio: 9.68%
  • Average Volume: 255,021 shs.
  • Beta: 1.58
  • Short Ratio: 15.43

Frequently Asked Questions for Repligen (NASDAQ:RGEN)

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Thursday, May, 4th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The firm earned $30.59 million during the quarter, compared to analysts' expectations of $29.28 million. Repligen had a return on equity of 10.16% and a net margin of 6.89%. The business's revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.12 earnings per share. View Repligen's Earnings History.

When will Repligen make its next earnings announcement?

Repligen is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Repligen.

Where is Repligen's stock going? Where will Repligen's stock price be in 2017?

3 equities research analysts have issued 1 year price objectives for Repligen's stock. Their predictions range from $30.00 to $40.00. On average, they expect Repligen's share price to reach $35.67 in the next twelve months. View Analyst Ratings for Repligen.

Who are some of Repligen's key competitors?

Who owns Repligen stock?

Repligen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.78%), TimesSquare Capital Management LLC (5.82%), OppenheimerFunds Inc. (5.69%), Vanguard Group Inc. (5.35%), FMR LLC (3.71%) and Conestoga Capital Advisors LLC (3.59%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Who sold Repligen stock? Who is selling Repligen stock?

Repligen's stock was sold by a variety of institutional investors in the last quarter, including Kalmar Investments Inc. DE, Renaissance Technologies LLC, Bank of New York Mellon Corp, Oxford Asset Management, Alliancebernstein L.P., Russell Investments Group Ltd., Schwab Charles Investment Management Inc. and FMR LLC. Company insiders that have sold Repligen stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.

Who bought Repligen stock? Who is buying Repligen stock?

Repligen's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., TimesSquare Capital Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Cortina Asset Management LLC, Vanguard Group Inc., Conestoga Capital Advisors LLC and Schroder Investment Management Group. View Insider Buying and Selling for Repligen.

How do I buy Repligen stock?

Shares of Repligen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Repligen stock cost?

One share of Repligen stock can currently be purchased for approximately $38.86.

Analyst Ratings

Consensus Ratings for Repligen (NASDAQ:RGEN) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $35.67 (8.22% downside)

Analysts' Ratings History for Repligen (NASDAQ:RGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/21/2017First AnalysisReiterated RatingEqual Weight$40.00LowView Rating Details
12/21/2016Jefferies Group LLCReiterated RatingHold$28.00 -> $30.00N/AView Rating Details
12/18/2016StephensSet Price TargetBuy$37.00N/AView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Repligen (NASDAQ:RGEN)
Earnings by Quarter for Repligen (NASDAQ:RGEN)
Earnings History by Quarter for Repligen (NASDAQ:RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Repligen (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.54
2018 EPS Consensus Estimate: $0.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20172$0.13$0.13$0.13
Q4 20173$0.12$0.13$0.13
Q1 20182$0.16$0.17$0.17
Q2 20181$0.17$0.17$0.17
Q3 20181$0.16$0.16$0.16
Q4 20181$0.17$0.17$0.17
(Data provided by Zacks Investment Research)


Dividend History for Repligen (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Repligen (NASDAQ:RGEN)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 94.35%
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Repligen (NASDAQ:RGEN)
Latest Headlines for Repligen (NASDAQ:RGEN)
DateHeadline logoRepligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference - May 24 at 9:46 AM logoFirst Analysis Analysts Cut Earnings Estimates for Repligen Co. (RGEN) - May 24 at 7:30 AM logoZacks: Repligen Co. (RGEN) Given $38.00 Consensus Price Target by Analysts - May 16 at 6:42 PM logo$31.47 Million in Sales Expected for Repligen Co. (RGEN) This Quarter - May 12 at 3:44 PM logoRepligen Co. (RGEN) Lifted to "Buy" at Zacks Investment Research - May 11 at 9:44 AM logoRepligen Co. (RGEN) Expected to Post Earnings of $0.16 Per Share - May 10 at 7:42 AM logoRepligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference - May 9 at 2:48 PM logoEquities Analysts Issue Forecasts for Repligen Co.'s Q2 2017 Earnings (RGEN) - May 8 at 8:21 AM logoQ3 2017 EPS Estimates for Repligen Co. (RGEN) Boosted by Jefferies Group - May 5 at 10:56 AM logoTrade of the Day: Repligen (NASDAQ:RGEN) - May 5 at 8:26 AM logoEdited Transcript of RGEN earnings conference call or presentation 4-May-17 12:30pm GMT - May 5 at 12:45 AM logoRepligen Co. (RGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - May 4 at 10:26 PM logoInvestor Network: Repligen Corporation to Host Earnings Call - May 4 at 7:45 PM logoRepligen Reports First Quarter 2017 Financial Results - May 4 at 7:45 PM logoRepligen tops Street 1Q forecasts - May 4 at 7:54 AM logoRepligen (RGEN) Receiving Somewhat Favorable Press Coverage, AlphaOne Reports - May 3 at 1:03 AM logoETFs with exposure to Repligen Corp. : May 1, 2017 - May 1 at 6:48 PM logoFavorable News Coverage Extremely Likely to Impact Repligen (RGEN) Share Price - April 27 at 4:24 PM logoSomewhat Positive Press Coverage Somewhat Unlikely to Impact Repligen (RGEN) Share Price - April 23 at 5:51 PM logoRepligen Co. (RGEN) Now Covered by First Analysis - April 21 at 10:16 PM logoETFs with exposure to Repligen Corp. : April 21, 2017 - April 21 at 7:18 PM logoRepligen to Report First Quarter 2017 Financial Results - April 21 at 8:33 AM logoRepligen (RGEN) Earning Somewhat Negative Media Coverage, Study Finds - April 20 at 8:35 PM logoRepligen Co. (RGEN) Expected to Announce Earnings of $0.13 Per Share - April 19 at 10:39 AM logoZacks: Repligen Co. (RGEN) Given $35.33 Consensus Price Target by Brokerages - April 17 at 11:31 AM logoRepligen (RGEN) Getting Somewhat Negative Media Coverage, Analysis Finds - April 14 at 3:32 PM logoRepligen Co. (RGEN) Short Interest Update - April 14 at 3:16 PM logoETFs with exposure to Repligen Corp. : April 7, 2017 - April 7 at 7:54 PM logo Brokerages Set $35.33 Target Price for Repligen Co. (RGEN) - March 31 at 2:08 PM logoInsider Selling: Repligen Co. (RGEN) Director Sells 2,521 Shares of Stock - March 22 at 8:06 PM logoInsider Selling: Repligen Co. (RGEN) Director Sells 4,000 Shares of Stock - March 22 at 8:04 PM logoRepligen Co. (RGEN) VP Sells $422,917.92 in Stock - March 22 at 7:44 PM logoRepligen Co. (RGEN) CFO Sells $66,643.19 in Stock - March 21 at 10:16 PM logoREPLIGEN CORP Financials - March 1 at 7:45 PM logoREPLIGEN CORP Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi - March 1 at 7:45 PM logoTop 3 Healthcare Penny Stocks for 2017 - March 1 at 12:06 PM logoEdited Transcript of RGEN earnings conference call or presentation 22-Feb-17 1:30pm GMT - February 23 at 12:43 AM logoRepligen's (RGEN) CEO Tony Hunt on Q4 2016 Results - Earnings Call Transcript - February 22 at 7:41 PM logoRepligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017 - February 22 at 9:34 AM logo7:32 am Repligen beats by $0.01, beats on revs; guides FY17 EPS in-line, revs in-line - February 22 at 9:34 AM logoREPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - February 22 at 9:34 AM logoRepligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017 - February 16 at 7:09 PM logoRepligen upgraded by Piper Jaffray - February 14 at 5:37 AM logoThe Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen - February 7 at 12:39 AM logoRepligen Corporation (RGEN) Presents At 35th Annual J.P. Morgan Healthcare Conference - January 14 at 5:41 AM logoRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference - GlobeNewswire (press release) - January 5 at 1:17 AM logoRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference - January 4 at 8:16 PM logo6:58 am Repligen acquires TangenX Technology for $39 mln in cash; RGEN expects earnings accretion in 2017 - December 16 at 12:34 AM logoRepligen Acquires TangenX Technology Corporation - December 16 at 12:34 AM logoUPDATE -- Repligen Acquires TangenX Technology Corporation - December 16 at 12:34 AM



Repligen (RGEN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff